FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer

Share:

Listens: 0

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

Science

FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer FDA medical oncologists discuss the agency’s December 2016 accelerated approval of rucaparib for treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer who have been treated with two or more chemotherapies.